Dry Powder Inhaler Market Size Is Expected To Reach US$ 1.3 Billion By 2031

The market for dry powder inhalers is anticipated to reach US$ 1.3 billion by 2031, growing at a CAGR of 7.2% from 2021 to 2031. By 2031, the industry is anticipated to provide an absolute dollar potential of around US$ 458 Mn. More than 35% of the world's inhaler market is currently made up of sales of dry powder inhalers.

For More insights into the, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=7083?SR

Analysis of Dry Powder Inhaler Sales (2016–2020) Compared to Market Outlook (202–2031).

The dry powder inhaler device market is anticipated to expand significantly due to the rise in respiratory disorders such asthma, chronic obstructive pulmonary disease (COPD), emphysema, and bronchitis.

The increased use of dry powder inhalers (DPI) around the world is largely due to rising respiratory disorders like asthma and chronic obstructive pulmonary disease, an increase in per capita healthcare spending, and rising air pollution levels, particularly in developing nations.Fact.MR forecasts that the market will stay stable, growing at a CAGR of 7.2% between 2021 and 2031 as opposed to the CAGR of 5.8% recorded between 2016 and 2020.

Manufacturers are engaged in competition. Limiting Market Entry for New Players

The major players in the dry inhaler market are progressively reorienting their efforts to improve retail as a distribution channel and develop efficient marketing plans. The use of dry powder inhaler devices has increased in North America as the prevalence of geriatrics and breathing disorders like asthma has increased.

In this extremely competitive market, entering the market is not simple. The main methods used by market players are product launches, mergers and acquisitions, joint ventures, and geographic expansions.

For instance, Hovione Technology purchased the rights to manufacture and market the multi-use, incredibly economical Papillon DPI dry powder inhaler device, which was invented by Dr. Klaus-Dieter Beller and granted a patent.

Key Players:

AstraZenecaGlaxoSmithKline plcVectura Group plcBoehringer Ingelheim GmbHOtsuka Pharmaceutical Co. Ltd.Norton HealthcareRespira Therapeutics, Inc.CheisiCiplaHovione3MOPKOTeva

Get Customization on this Report Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=7083

Regional Analysis:

 With a current market share of 35.7%, the dry powder inhaler market in North America is expected to represent the greatest portion of global sales. This can be due to the existence of a strong healthcare infrastructure, significant market players, and ongoing investments in R&D activities.

 Additionally, it is predicted that the market for dry powder inhaler devices in the United States would rise significantly over the next ten years due to rising rates of asthma and other respiratory disorders as well as an aging population.

 During the assessment period of 2021–2031, Asia Pacific is anticipated to be a significant-growing market for the sales of dry powder inhaler devices. This is a result of rising healthcare costs and fast developing medical infrastructure in nations like China and India, both of which are expected to drive market expansion in the ensuing years.

Key Segments of Industry:

By Product TypeCapsule-based DevicesBlister-based DevicesReservoir/Cartridge-based DevicesOthersBy ApplicationBronchitisChronic Obstructive Pulmonary Diseases (COPD)AsthmaOthersBy Sales ChannelOffline ChannelsHospital PharmaciesRetail PharmaciesDrug StoresOther Sales ChannelsOnline Channels

For More in-depth competitive analysis, Buy Now:
https://www.factmr.com/checkout/7083

Contact:

US Sales Office

11140 Rockville Pike

Suite 400

Rockville, MD 20852

United States

Tel: +1 (628) 251-1583, +353-1-4434-232

Email: [email protected]